These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 24007533)

  • 21. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.
    Reynes J; Cournil A; Peyriere H; Psomas C; Guiller E; Chatron M; Cristol JP; Badiou S
    AIDS; 2013 May; 27(8):1295-302. PubMed ID: 23925378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy.
    Chitra P; Bakthavatsalam B; Palvannan T
    Clin Chim Acta; 2011 May; 412(11-12):1151-4. PubMed ID: 21300045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
    Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
    J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
    Vassallo M; Durant J; Lebrun-Frenay C; Fabre R; Ticchioni M; Andersen S; DeSalvador F; Harvey-Langton A; Dunais B; Cohen-Codar I; Montagne N; Cua E; Fredouille-Heripret L; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    HIV Med; 2015 Aug; 16(7):431-40. PubMed ID: 25981452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased carotid intima-media thickness is not associated with T-cell activation nor with cytomegalovirus in HIV-infected never-smoker patients.
    Goulenok T; Boyd A; Larsen M; Fastenackels S; Boccara F; Meynard JL; Hadour N; Samri A; Desvarieux M; Autran B; Appay V; Girard PM; Sauce D;
    AIDS; 2015 Jan; 29(3):287-93. PubMed ID: 25686677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV.
    Han WM; Apornpong T; Kerr SJ; Hiransuthikul A; Gatechompol S; Do T; Ruxrungtham K; Avihingsanon A
    AIDS Res Ther; 2018 Sep; 15(1):13. PubMed ID: 30261902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
    Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
    J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Premature age-related comorbidities among HIV-infected persons compared with the general population.
    Guaraldi G; Orlando G; Zona S; Menozzi M; Carli F; Garlassi E; Berti A; Rossi E; Roverato A; Palella F
    Clin Infect Dis; 2011 Dec; 53(11):1120-6. PubMed ID: 21998278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses.
    Lichtenstein KA; Armon C; Nagabhushanam V; Efaw BJ; Frazer-Abel A; Hiserote ME; Alam R
    Antivir Ther; 2012; 17(7):1301-9. PubMed ID: 22948290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort.
    van Lelyveld SF; Gras L; Kesselring A; Zhang S; De Wolf F; Wensing AM; Hoepelman AI;
    AIDS; 2012 Feb; 26(4):465-74. PubMed ID: 22112603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy.
    Ando M; Yanagisawa N; Ajisawa A; Tsuchiya K; Nitta K
    Nephrol Dial Transplant; 2011 Oct; 26(10):3224-9. PubMed ID: 21372250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
    Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
    Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.